Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.
Yu C, Geng S, Yang B, Deng Y, Li F, Kang X, Bi M, Zhang F, Zhao Y, Pan W, Tian Z, Xu J, Zhang Z, Yu N, Duan X, Guo S, Sun Q, Li W, Tao J, Liu Z, Yin Y, Wang G.
Yu C, et al. Among authors: tao j.
Chin Med J (Engl). 2024 May 20;137(10):1190-1198. doi: 10.1097/CM9.0000000000002873. Epub 2024 Jan 9.
Chin Med J (Engl). 2024.
PMID: 38192233
Free PMC article.
Clinical Trial.